Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? (Q38260277)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

review article

1 reference

title

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

amyotrophic lateral sclerosis

21 February 2020

main subject

0 references

author

Vincenzo Silani

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1

Hiroshi Mitsumoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Benjamin R Brooks

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1127-1138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

AMPA receptor calcium permeability, GluR2 expression, and selective motoneuron vulnerability

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Critical review of gangliosides and thyrotropin-releasing hormone in peripheral neuromuscular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Neurotrophic factors and neuromuscular disease: I. General comments, the neurotrophin family, and neuropoietic cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Autoimmunity and ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Oxidative stress in ALS: key role in motor neuron injury and therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Lithium delays progression of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Emerging drugs for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Controversies and priorities in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Trends in risks associated with new drug development: success rates for investigational drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A clinical trial of creatine in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Trial of celecoxib in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Brain and plasma riluzole pharmacokinetics: effect of minocycline combination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Phase II/III randomized trial of TCH346 in patients with ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis. Committee on Health Care Issues, American Neurological Association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Lithium therapy in ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Comments on Fornai et al. (PNAS/ Feb 2008)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

The unregulated commercialization of stem cell treatments: a global perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Olfactory ensheathing glia injections in Beijing: misleading patients with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

No benefits from experimental treatment with olfactory ensheathing cells in patients with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Guidelines for preclinical animal research in ALS/MND: A consensus meeting

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Policy: NIH plans to enhance reproducibility

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Prognostic factors in ALS: A critical review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Can Selection of Rapidly Progressing Patients Shorten Clinical Trials in Amyotrophic Lateral Sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Electrodiagnostic criteria for diagnosis of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Commentary on ‘A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS’

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Pivotal studies of orphan drugs approved for neurological diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A double-blind study of L-threonine in patients with spinal spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Noninvasive ventilation in ALS: indications and effect on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

RETRACTED: Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A randomized controlled trial of resistance exercise in individuals with ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Effects of aerobic exercise therapy and cognitive behavioural therapy on functioning and quality of life in amyotrophic lateral sclerosis: protocol of the FACTS-2-ALS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: A prospective interventional study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the Am

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970129-2

7 January 2021

10.1016/S1474-4422(14)70129-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25316019%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference